JP6651450B2 - 酪酸、葉酸、又はナイアシンの腸内産生を増加させるための、及び／又はコハク酸の腸内産生を低下させるための、微生物を含む組成物の使用 - Google Patents

酪酸、葉酸、又はナイアシンの腸内産生を増加させるための、及び／又はコハク酸の腸内産生を低下させるための、微生物を含む組成物の使用 Download PDF

Info

Publication number
JP6651450B2
JP6651450B2 JP2016539667A JP2016539667A JP6651450B2 JP 6651450 B2 JP6651450 B2 JP 6651450B2 JP 2016539667 A JP2016539667 A JP 2016539667A JP 2016539667 A JP2016539667 A JP 2016539667A JP 6651450 B2 JP6651450 B2 JP 6651450B2
Authority
JP
Japan
Prior art keywords
composition
intestinal
lactobacillus
acid
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016539667A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016529309A (ja
JP2016529309A5 (cg-RX-API-DMAC7.html
Inventor
ビッフィ アンドレーア
ビッフィ アンドレーア
ロッシ ルッジェーロ
ロッシ ルッジェーロ
フィオーレ ウォルター
フィオーレ ウォルター
ドメニコ グリエルメッティ シモーネ
ドメニコ グリエルメッティ シモーネ
Original Assignee
ソファル ソチエタ ペル アツィオニ
ソファル ソチエタ ペル アツィオニ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ソファル ソチエタ ペル アツィオニ, ソファル ソチエタ ペル アツィオニ filed Critical ソファル ソチエタ ペル アツィオニ
Publication of JP2016529309A publication Critical patent/JP2016529309A/ja
Publication of JP2016529309A5 publication Critical patent/JP2016529309A5/ja
Application granted granted Critical
Publication of JP6651450B2 publication Critical patent/JP6651450B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
    • A23V2200/3202—Prebiotics, ingredients fermented in the gastrointestinal tract by beneficial microflora
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
    • A23V2200/3204—Probiotics, living bacteria to be ingested for action in the digestive tract
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/165—Paracasei
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2016539667A 2013-09-06 2014-09-05 酪酸、葉酸、又はナイアシンの腸内産生を増加させるための、及び／又はコハク酸の腸内産生を低下させるための、微生物を含む組成物の使用 Expired - Fee Related JP6651450B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT001467A ITMI20131467A1 (it) 2013-09-06 2013-09-06 Uso di una composizione comprendente microrganismi per aumentare la produzione intestinale di acido butirrico, di acido folico o di niacina e/o per diminuire la produzione intestinale di acido succinico
ITMI2013A001467 2013-09-06
PCT/IB2014/064285 WO2015033305A1 (en) 2013-09-06 2014-09-05 Use of a composition comprising microorganisms to increase the intestinal production of butyric acid, folic acid or niacin and/or decrease the intestinal production of succinic acid

Publications (3)

Publication Number Publication Date
JP2016529309A JP2016529309A (ja) 2016-09-23
JP2016529309A5 JP2016529309A5 (cg-RX-API-DMAC7.html) 2017-10-19
JP6651450B2 true JP6651450B2 (ja) 2020-02-19

Family

ID=49354800

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016539667A Expired - Fee Related JP6651450B2 (ja) 2013-09-06 2014-09-05 酪酸、葉酸、又はナイアシンの腸内産生を増加させるための、及び／又はコハク酸の腸内産生を低下させるための、微生物を含む組成物の使用

Country Status (26)

Country Link
US (2) US11839634B2 (cg-RX-API-DMAC7.html)
EP (1) EP3041489B1 (cg-RX-API-DMAC7.html)
JP (1) JP6651450B2 (cg-RX-API-DMAC7.html)
CN (2) CN105916513A (cg-RX-API-DMAC7.html)
AU (1) AU2014316688B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016005059B1 (cg-RX-API-DMAC7.html)
CA (1) CA2923392C (cg-RX-API-DMAC7.html)
CY (1) CY1123127T1 (cg-RX-API-DMAC7.html)
DK (1) DK3041489T3 (cg-RX-API-DMAC7.html)
EA (1) EA036534B1 (cg-RX-API-DMAC7.html)
ES (1) ES2805471T3 (cg-RX-API-DMAC7.html)
HK (1) HK1224192A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20201065T1 (cg-RX-API-DMAC7.html)
HU (1) HUE050146T2 (cg-RX-API-DMAC7.html)
IL (2) IL244392B (cg-RX-API-DMAC7.html)
IT (1) ITMI20131467A1 (cg-RX-API-DMAC7.html)
LT (1) LT3041489T (cg-RX-API-DMAC7.html)
ME (1) ME03805B (cg-RX-API-DMAC7.html)
MX (1) MX375509B (cg-RX-API-DMAC7.html)
PL (1) PL3041489T3 (cg-RX-API-DMAC7.html)
PT (1) PT3041489T (cg-RX-API-DMAC7.html)
RS (1) RS60518B1 (cg-RX-API-DMAC7.html)
SG (2) SG11201601662SA (cg-RX-API-DMAC7.html)
SI (1) SI3041489T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202000362T1 (cg-RX-API-DMAC7.html)
WO (1) WO2015033305A1 (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
ITMI20131467A1 (it) 2013-09-06 2015-03-07 Sofar Spa Uso di una composizione comprendente microrganismi per aumentare la produzione intestinale di acido butirrico, di acido folico o di niacina e/o per diminuire la produzione intestinale di acido succinico
MA39710A (fr) 2014-04-23 2015-10-29 Sofar Spa Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
JP6439037B2 (ja) 2015-06-15 2018-12-19 フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ 細菌株を含む組成物
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
MA45327A (fr) 2016-05-13 2019-03-20 Sofar Spa Utilisation de probiotiques pour améliorer l'absorption des protéines
MA45288A (fr) 2016-06-08 2019-04-17 Sofar Spa Nouvelle utilisation médicale de probiotiques
TW201821093A (zh) 2016-07-13 2018-06-16 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
IT201600122724A1 (it) 2016-12-02 2018-06-02 Sofar Spa Exopolysaccharides and uses thereof
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
IT201600127498A1 (it) * 2016-12-16 2018-06-16 Sofar Spa Probiotici per uso nella diverticolosi e malattia diverticolare
GB201704525D0 (en) 2017-03-22 2017-05-03 Central Glass Co Ltd Vehicle glass window with electrical connector soldered by lead-free solder
CA3064171A1 (en) * 2017-05-22 2018-11-29 4D Pharma Research Limited Compositions comprising bacterial strains
EP3630942B1 (en) 2017-05-24 2022-11-30 4D Pharma Research Limited Compositions comprising bacterial strain
JP6884889B2 (ja) 2017-06-14 2021-06-09 フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ 細菌株を含む組成物
JP2020523326A (ja) 2017-06-14 2020-08-06 フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ 細菌株を含む組成物
SMT202100069T1 (it) 2017-06-14 2021-03-15 4D Pharma Res Limited Composizioni comprendenti ceppi batterici
IT201700101704A1 (it) * 2017-09-12 2019-03-12 Sofar Spa Nuovo uso per trattamento delle infezioni da clostridium difficile
WO2019111189A1 (en) * 2017-12-06 2019-06-13 Sofar S.P.A. Composition based on probiotics and uses thereof
WO2019141780A1 (en) * 2018-01-17 2019-07-25 Consorcio Centro de Investigación Biomédica en Red, M.P. Targeted interventions directed at reducing the levels of circulating succinate in a subject, and kits and method for determining effectiveness of said interventions
CN110358712B (zh) * 2019-07-26 2021-11-09 浙江一鸣食品股份有限公司 一种乳酸菌组合物及其应用
CN110358714A (zh) * 2019-08-01 2019-10-22 浙江一鸣食品股份有限公司 一种高产叶酸的乳酸菌组合物
CN110669697B (zh) * 2019-10-31 2022-07-15 微康益生菌(苏州)股份有限公司 一种高产短链脂肪酸的干酪乳杆菌、培养方法及其应用
US11751597B2 (en) 2019-11-05 2023-09-12 Alfasigma S.P.A. Compositions comprising bacterial strains for use in increasing the bioavailability of amino acids derived from proteins, and related food product methods and systems

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0517363A (ja) 1991-07-11 1993-01-26 Yakult Honsha Co Ltd 抗炎症剤及びそれを含有する化粧料
US5716615A (en) 1992-02-10 1998-02-10 Renata Maria Anna Cavaliere Vesely Dietary and pharmaceutical compositions containing lyophilized lactic bacteria, their preparation and use
US5531989A (en) 1994-10-28 1996-07-02 Metagenics, Inc. Immunoglobulin and fiber-containing composition for human gastrointestinal health
CN1066926C (zh) 1996-04-08 2001-06-13 钟春燕 将椰子水发酵制作的食用纤维及其生产方法
US6461607B1 (en) 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
CZ9900769A3 (cs) 1999-03-04 2000-10-11 Petr Ing. Drsc. Hušek Použití špičky s filtrem k vytvoření sloupce sorbentu s definovaným objemem v prostoru pod filtrem
US20020090416A1 (en) 1999-03-09 2002-07-11 Philip Connolly Method of enhancing absorption and utilization of protein
IT1307850B1 (it) * 1999-03-15 2001-11-19 Italmed Di Galli Giovanna E Pa Composizione farmaceutica a base di fermenti lattici e carboidratinon assorbibili contenente un sale di calcio ed un sale di alluminio
EP1145643A1 (en) 2000-04-10 2001-10-17 Phillip Connolly Improved milk protein concentrate
US20040170617A1 (en) 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
RU2182008C1 (ru) 2000-10-20 2002-05-10 Самойленко Игорь Иннокентьевич Вводимая перорально, ректально или интравагинально композиция, содержащая живые бактерии
PE20030284A1 (es) 2001-07-26 2003-05-01 Alimentary Health Ltd Cepas de bifidobacterium
FI20020078A7 (fi) * 2002-01-15 2003-07-16 Danisco Immuunijärjestelmän stimulointi polydextroosilla
US6881419B2 (en) * 2002-04-09 2005-04-19 William E. Lovett Vitamin formulation for enhancing bone strength
CN1627948A (zh) 2002-04-24 2005-06-15 麦迪卡博公司 治疗炎症性肠病的组合物和试剂盒
JP2005534315A (ja) 2002-08-06 2005-11-17 ダニスコ エイ／エス 食品および薬学的組成物中に細胞外多糖類を産生する乳酸桿菌の使用
AU2002951270A0 (en) 2002-09-06 2002-09-19 Vri Biomedical Ltd Probiotic Bacterium and Methods of Use
WO2005001109A2 (en) 2003-05-06 2005-01-06 Government Of The United States Of America As Represented By The Sercretary Of The Department Of Health And Human Services National Institutes Of Health Methods and compositions to detect microbes in fecal samples
US20100112088A1 (en) * 2003-08-29 2010-05-06 Jay Pravda Materials and methods for treatment of disorders associated with oxidative stress
CA2557543A1 (en) 2004-02-27 2005-09-09 Stichting Laboratorium Voor Infectieziekten Method for detecting a microorganism in a fecal specimen
KR20060114370A (ko) 2004-03-04 2006-11-06 이엘씨 매니지먼트 엘엘씨 락토바실러스(Ｌａｃｔｏｂａｃｉｌｌｕｓ) 추출물을이용한 피부 치료 방법
EP2280085A3 (en) 2004-11-01 2011-02-23 George Mason University Compositions and methods for diagnosing colon disorders
SG161234A1 (en) * 2005-04-06 2010-05-27 Novartis Ag A method and composition for nutritionally improving glucose control and insulin action
FI20051319L (fi) 2005-12-22 2007-06-23 Cyflo Oy Menetelmä eläimen ja/tai ihmisen ravitsemuksen ja hyvinvoinnin ja eläinten tuottavuuden seuraamiseksi ja kehittämiseksi
CN1840206A (zh) 2006-01-19 2006-10-04 上海交通大学 人源菌群仔猪模型的构建及仔猪肠道中菌群分子检测方法
ES2426038T3 (es) 2006-02-21 2013-10-18 National University Corporation University Of Toyama Procedimiento rápido para identificar el microorganismo causante de una enfermedad infecciosa
EP1992645A4 (en) 2006-02-24 2011-03-09 Q P Corp NOVEL HYALURONIC ACID WITH LOW MOLECULAR WEIGHT AND / OR SALT THEREOF, AND COSMETIC PREPARATION, PHARMACEUTICAL COMPOSITION AND EACH FOOD COMPOSITION USING THE SAME
EP2012596A1 (en) * 2006-05-03 2009-01-14 Anidral S.R.L. Symbiotic composition comprising non-digestible polysaccharides and bifidobacteria which metabolize them and its uses
WO2007140621A1 (en) 2006-06-09 2007-12-13 Nutravital Inc. Probiotic compositions and uses thereof
US20080069861A1 (en) 2006-09-19 2008-03-20 National Starch And Chemical Investment Holding Corporation Probiotic/Non-Probiotic Combinations
US20080081035A1 (en) * 2006-10-03 2008-04-03 National Enzyme Company Therapeutic protease compositions
JP5285617B2 (ja) 2006-12-18 2013-09-11 アドバンスド バイオニュートリション コーポレーション 生きたプロバイオティクスを含む乾燥食物製品
EP1972208A1 (en) * 2007-03-16 2008-09-24 Kirin Holdings Kabushiki Kaisha Composition for improving intestinal microflora
BRPI0809454A2 (pt) 2007-03-27 2014-09-09 Procter & Gamble Métodos e kits para a administração de probióticos
EP2155167A2 (en) 2007-06-04 2010-02-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
RU2469558C2 (ru) * 2007-07-06 2012-12-20 Н.В. Нютрисиа Применение пробиотиков и волокон при диарее
US8193155B2 (en) 2009-02-09 2012-06-05 Elc Management, Llc Method and compositions for treating skin
US20090098088A1 (en) 2007-10-10 2009-04-16 The Procter & Gamble Company Methods And Kits For The Treatment Of Diverticular Conditions
CN101240315A (zh) 2008-02-21 2008-08-13 上海交通大学 检测药物防癌效果的非损伤性分子方法
AU2009243066A1 (en) 2008-05-01 2009-11-05 The Procter & Gamble Company Methods and kits for the treatment of inflammatory bowel disorder conditions
WO2010008272A1 (en) 2008-07-15 2010-01-21 N.V. Nutricia Treatment of gut motility disorders
JP2010161944A (ja) 2009-01-13 2010-07-29 Syngen Biotech Co Ltd 新型カゼイ菌の亜種（ｓｇ９６）及びこれを含有する菌抑制組成物及びその用途
PL2403510T3 (pl) 2009-03-05 2020-06-29 Probiotical S.P.A. Szczepy bakteryjne o wysokiej aktywności przeciwzapalnej
WO2010103132A1 (es) 2009-03-10 2010-09-16 Hero España, S.A. Aislamiento, identificación y caracterización de cepas con actividad probiótica a partir de heces de lactantes alimentados exclusivamente con leche materna
JP2013505289A (ja) 2009-09-23 2013-02-14 トーマス・ジュリアス・ボロディ 腸管感染症の治療法
WO2011060123A1 (en) * 2009-11-12 2011-05-19 Nestec S.A. Nutritional composition for promoting gut microbiota balance and health
AU2010334993B2 (en) * 2009-12-22 2015-07-09 Probi Ab Non-fermented compositions comprising a cereal based fraction and a probiotic and uses thereof
US8575130B2 (en) 2010-01-04 2013-11-05 Holy Stone Healthcare Co., Ltd. Mixture of hyaluronic acid for treating and preventing inflammatory bowel disease
ITUD20100112A1 (it) 2010-06-09 2011-12-10 Farma Derma S R L Preparazione per uso vaginale e rettale e relativo procedimento di produzione
WO2012135499A1 (en) 2011-03-31 2012-10-04 Ganeden Biotech, Inc. Probiotic sports nutrition compositions
US20140072621A1 (en) 2011-05-09 2014-03-13 The Cleveland Clinic Foundation Composition and method to improve intestinal health
RU2748839C2 (ru) 2011-06-20 2021-05-31 Х.Дж. Хайнц Компани Брэндс Ллк Композиции, способы и наборы для стимулирования мукозальной иммунной системы
GB201219873D0 (en) 2012-11-05 2012-12-19 Multigerm Uk Entpr Ltd Diverticulitis treatment
CN102919922A (zh) 2012-11-08 2013-02-13 黑龙江省轻工科学研究院 一种复合益生菌发酵蓝莓果汁粉的制备方法
KR20150134356A (ko) 2013-03-05 2015-12-01 리엑스유니버시테이트 그로닝겐 염증을 억제하기 위한 페칼리 박테리움 프라우스니치이 htf-f (dsm 26943)의 용도
KR102250588B1 (ko) 2013-07-02 2021-05-12 오스트리아노바 싱가포르 피티이 리미티드 캡슐화 세포의 동결-건조 방법, 동결 건조된 캡슐화 세포, 동결 건조된 캡슐화 세포를 함유하는 조성물, 및 상기 세포 및 조성물의 용도
ITMI20131473A1 (it) 2013-09-06 2015-03-07 Sofar Spa Metodo per valutare gli effetti di una composizione comprendente microrganismi sul microbiota intestinale
ITMI20131467A1 (it) 2013-09-06 2015-03-07 Sofar Spa Uso di una composizione comprendente microrganismi per aumentare la produzione intestinale di acido butirrico, di acido folico o di niacina e/o per diminuire la produzione intestinale di acido succinico
MA39710A (fr) 2014-04-23 2015-10-29 Sofar Spa Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin
WO2015172191A1 (en) 2014-05-12 2015-11-19 Medlab Ip Pty Ltd Probiotic compositions and uses thereof for treatment of obesity-related disorders
ES2610994T3 (es) 2014-08-26 2017-05-04 Chr. Hansen A/S Bifidobacterium animalis subsp. lactis para el uso en la reducción del dolor abdominal en una mujer postmenopáusica
WO2017195182A1 (en) 2016-05-13 2017-11-16 Sofar S.P.A. Use of probiotics for improving protein absorption
MA45327A (fr) 2016-05-13 2019-03-20 Sofar Spa Utilisation de probiotiques pour améliorer l'absorption des protéines
MA45288A (fr) 2016-06-08 2019-04-17 Sofar Spa Nouvelle utilisation médicale de probiotiques
IT201600122724A1 (it) 2016-12-02 2018-06-02 Sofar Spa Exopolysaccharides and uses thereof
IT201600127498A1 (it) 2016-12-16 2018-06-16 Sofar Spa Probiotici per uso nella diverticolosi e malattia diverticolare
EP3554517B1 (en) 2016-12-16 2023-09-13 Compagnie Gervais Danone Probiotic composition comprising lactobacillus rhamnosus and lactobacillus paracasei strains
WO2019019961A1 (zh) 2017-07-26 2019-01-31 海思科医药集团股份有限公司 防治消化道和/或皮肤反应的菌群及其应用
IT201700101704A1 (it) 2017-09-12 2019-03-12 Sofar Spa Nuovo uso per trattamento delle infezioni da clostridium difficile
WO2019111189A1 (en) 2017-12-06 2019-06-13 Sofar S.P.A. Composition based on probiotics and uses thereof
CN108743851A (zh) 2018-08-09 2018-11-06 深圳市博奥生物科技有限公司 一种复合益生菌粉的制备方法及复合益生菌粉
IT201900016805A1 (it) 2019-09-20 2021-03-20 Sofar Spa Ceppi batterici, loro composizioni e loro uso per il trattamento di disturbi gastrointestinali
IT201900016865A1 (it) 2019-09-20 2021-03-20 Sofar Spa Composizioni a base di ceppi batterici e loro uso come antinfiammatori
IT201900016850A1 (it) 2019-09-20 2021-03-20 Sofar Spa Composizioni a base di ceppi batterici e estratti di bacche e loro uso come antinfiammatori
IT201900016811A1 (it) 2019-09-20 2021-03-20 Sofar Spa Ceppi batterici, loro composizioni e loro uso per il trattamento di disturbi gastrointestinali
IT201900020422A1 (it) 2019-11-05 2021-05-05 Sofar Spa Composizioni comprendenti ceppi di batteri per uso per aumentare la biodisponibilità degli amminoacidi derivanti da proteine
US11751597B2 (en) 2019-11-05 2023-09-12 Alfasigma S.P.A. Compositions comprising bacterial strains for use in increasing the bioavailability of amino acids derived from proteins, and related food product methods and systems

Also Published As

Publication number Publication date
MX2016002765A (es) 2016-08-03
ES2805471T3 (es) 2021-02-12
PL3041489T3 (pl) 2020-11-02
SG11201601662SA (en) 2016-04-28
CY1123127T1 (el) 2021-10-29
IL269107A (en) 2019-11-28
EP3041489A1 (en) 2016-07-13
BR112016005059B1 (pt) 2022-01-04
IL244392A0 (en) 2016-04-21
PT3041489T (pt) 2020-07-16
SMT202000362T1 (it) 2020-09-10
CA2923392A1 (en) 2015-03-12
EA036534B1 (ru) 2020-11-20
WO2015033305A1 (en) 2015-03-12
JP2016529309A (ja) 2016-09-23
US20240050497A1 (en) 2024-02-15
HRP20201065T1 (hr) 2020-12-11
RS60518B1 (sr) 2020-08-31
DK3041489T3 (da) 2020-07-20
ITMI20131467A1 (it) 2015-03-07
IL244392B (en) 2019-09-26
IL269107B (en) 2021-01-31
EP3041489B1 (en) 2020-04-15
US20160296569A1 (en) 2016-10-13
AU2014316688A1 (en) 2016-03-24
HUE050146T2 (hu) 2020-11-30
AU2014316688B2 (en) 2020-02-27
ME03805B (me) 2021-04-20
EA201690464A1 (ru) 2016-08-31
CN115804798A (zh) 2023-03-17
SG10202001331PA (en) 2020-04-29
US11839634B2 (en) 2023-12-12
SI3041489T1 (sl) 2020-10-30
LT3041489T (lt) 2020-09-25
HK1224192A1 (zh) 2017-08-18
MX375509B (es) 2025-03-06
BR112016005059A2 (pt) 2017-11-21
CN105916513A (zh) 2016-08-31
CA2923392C (en) 2023-01-03

Similar Documents

Publication Publication Date Title
JP6651450B2 (ja) 酪酸、葉酸、又はナイアシンの腸内産生を増加させるための、及び／又はコハク酸の腸内産生を低下させるための、微生物を含む組成物の使用
Singh et al. Probiotics: A review
De Vrese et al. Probiotics and prebiotics: effects on diarrhea
Hays et al. Probiotics and growth in preterm infants: a randomized controlled trial, PREMAPRO study
JP2021152062A (ja) 過敏性腸症候群の治療のための合成組成物および方法
CN105142654B (zh) 肠小型生物群中的毛螺菌科和与体重的关联
AU2019261707A1 (en) Prebiotics for reducing the risk of obesity later in life
AU2011351419A1 (en) A nutritional composition comprising fiber and probiotics for reducing stress-related intestinal symptoms
Radicioni et al. Survival of L. casei DG®(Lactobacillus paracasei CNCMI1572) in the gastrointestinal tract of a healthy paediatric population
AU2011351418A1 (en) Fiber and probiotics for reducing intestinal symptoms related to stress
Liu et al. Efficacy of pasteurised yoghurt in improving chronic constipation: A randomised, double-blind, placebo-controlled trial
WO2012089784A1 (en) Fiber and probiotics for reducing intestinal symptoms related to chronic stress
Stevens et al. Effect of a carotenoid-producing Bacillus strain on intestinal barrier integrity and systemic delivery of carotenoids: A randomised trial in animals and humans
CN116349815A (zh) 一种能够调节肠道菌群的活菌型益生菌固体饮料生产配方
US20220047659A1 (en) Symbiotic supplement formulation for improving intestinal microbiota
Varshney An analysis of probiotics
CN106974940A (zh) 厚壁菌类益生菌在治疗和预防肥胖及其相关疾病中的应用
Lunder Reviewing clinical studies of probiotics as dietary supplements: probiotics for gastrointestinal disorders, Helicobacter eradication, lactose malabsorption and inflammatory bowel disease (IBD)
Sharma et al. AN OVERVIEW: PROBIOTIC MICROBES
HK40090429A (zh) 含微生物的组合物增加丁酸、叶酸或烟酸的肠道生产和/或降低琥珀酸的肠道生产的应用
Khader Probiotics and Prebiotics as Functional Food Ingredients

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170905

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170905

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180612

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180911

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190514

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190814

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191114

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20191217

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200116

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200122

R150 Certificate of patent or registration of utility model

Ref document number: 6651450

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees